Evidence map›Paper›PMID 27768884›Full record

ArticleCell2016

Glucagon and Thyroid Hormone: A Championship Team.

Alan Saghatelian, Ben Cravatt

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Endocrine-Metabolic Crosstalk Between Diabetes Mellitus and Hypothyroidism: From Network Mechanisms to Translational Stratification.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alan SaghatelianSalk Institute for Biological Studies, Clayton Foundation Laboratories for Peptide Biology, 10010 N. Torrey Pines Rd, La Jolla, CA 92037, USA. Electronic address: asaghatelian@salk.edu.
Ben CravattDepartment of Chemical Physiology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA. Electronic address: cravatt@scripps.edu.
Salk Institute for Biological Studies · USScripps Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A bioactive peptide that combines glucagon with the thyroid hormone T3 lowers lipid levels, improves glucose tolerance, and promotes energy expenditure to treat symptoms and underlying causes of metabolic disease. The two active components both maximize their combined benefits and mitigate the negative consequences of treatment with each alone.

Indexed as

GlucagonThyroid HormonesEnergy MetabolismHumansInsulinPeptidesTriiodothyronineGlucagonInsulinPeptidesThyroid HormonesTriiodothyronine

Identifiers

PMID27768884
OpenAlexW2535058272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.